黑色素瘤治疗新方法的现代观点与分析

IF 0.1 Q4 MEDICINE, GENERAL & INTERNAL

Avances en Biomedicina Pub Date : 2023-10-05 DOI:10.33647/2074-5982-19-3-47-52

A. V. Safronenko, O. M. Kudelina, E. V. Gantsgorn, M. Kh.-B. Buraeva, M. Kh.-B. Buraeva, A. A. Miteneva, L. R. Shvelidze, D. A. Kalmykova, A. A. Ilyina, V. Z. Lachinov

{"title":"黑色素瘤治疗新方法的现代观点与分析","authors":"A. V. Safronenko, O. M. Kudelina, E. V. Gantsgorn, M. Kh.-B. Buraeva, M. Kh.-B. Buraeva, A. A. Miteneva, L. R. Shvelidze, D. A. Kalmykova, A. A. Ilyina, V. Z. Lachinov","doi":"10.33647/2074-5982-19-3-47-52","DOIUrl":null,"url":null,"abstract":"Melanoma is a malignant tumor that can rapidly develop resistance to treatment because of its high mutational activity. The introduction of tyrosine kinase receptor inhibitors (BRAF, MEK) and cytotoxic T lymphocyte antigen/receptor inhibitors (CTLA4, PD-1) into clinical practice has led to an increase in patient survival rates. In in vitro studies, combining PIK3 and MEK inhibitors demonstrate a pronounced reduction in tumor cell growth. The phenomenon of synthetic lethality is also promising, allowing the high mutational load of melanoma to be used as a tool for the development of more effective drugs.","PeriodicalId":40514,"journal":{"name":"Avances en Biomedicina","volume":"36 1","pages":"0"},"PeriodicalIF":0.1000,"publicationDate":"2023-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Modern Views and Analysis of Promising Approaches to the Treatment of Melanoma\",\"authors\":\"A. V. Safronenko, O. M. Kudelina, E. V. Gantsgorn, M. Kh.-B. Buraeva, M. Kh.-B. Buraeva, A. A. Miteneva, L. R. Shvelidze, D. A. Kalmykova, A. A. Ilyina, V. Z. Lachinov\",\"doi\":\"10.33647/2074-5982-19-3-47-52\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Melanoma is a malignant tumor that can rapidly develop resistance to treatment because of its high mutational activity. The introduction of tyrosine kinase receptor inhibitors (BRAF, MEK) and cytotoxic T lymphocyte antigen/receptor inhibitors (CTLA4, PD-1) into clinical practice has led to an increase in patient survival rates. In in vitro studies, combining PIK3 and MEK inhibitors demonstrate a pronounced reduction in tumor cell growth. The phenomenon of synthetic lethality is also promising, allowing the high mutational load of melanoma to be used as a tool for the development of more effective drugs.\",\"PeriodicalId\":40514,\"journal\":{\"name\":\"Avances en Biomedicina\",\"volume\":\"36 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.1000,\"publicationDate\":\"2023-10-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Avances en Biomedicina\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.33647/2074-5982-19-3-47-52\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Avances en Biomedicina","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33647/2074-5982-19-3-47-52","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

摘要

黑色素瘤是一种恶性肿瘤，由于其高突变活性，可以迅速对治疗产生耐药性。酪氨酸激酶受体抑制剂(BRAF, MEK)和细胞毒性T淋巴细胞抗原/受体抑制剂(CTLA4, PD-1)引入临床实践，导致患者生存率的提高。在体外研究中，联合使用PIK3和MEK抑制剂可以显著降低肿瘤细胞的生长。合成致死率的现象也很有希望，允许黑色素瘤的高突变负荷被用作开发更有效药物的工具。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Modern Views and Analysis of Promising Approaches to the Treatment of Melanoma

Melanoma is a malignant tumor that can rapidly develop resistance to treatment because of its high mutational activity. The introduction of tyrosine kinase receptor inhibitors (BRAF, MEK) and cytotoxic T lymphocyte antigen/receptor inhibitors (CTLA4, PD-1) into clinical practice has led to an increase in patient survival rates. In in vitro studies, combining PIK3 and MEK inhibitors demonstrate a pronounced reduction in tumor cell growth. The phenomenon of synthetic lethality is also promising, allowing the high mutational load of melanoma to be used as a tool for the development of more effective drugs.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Avances en Biomedicina MEDICINE, GENERAL & INTERNAL-

自引率

0.00%

发文量

审稿时长

14 weeks